AA
SLNO

ALPS Advisors’s Soleno Therapeutics SLNO Stock Holding History

ALPS Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,168
Closed -$1.47M – 1035
2024
Q3 		$1.47M Buy
29,168
+767
+3% +$36.7K 0.01% 407
2024
Q2 		$1.16M Buy
28,401
+6,887
+32% +$292K 0.01% 432
2024
Q1 		$921K Buy
21,514
+2,028
+10% +$91.7K 0.01% 505
2023
Q4 		$784K Buy
+19,486
New +$554K 0.01% 537

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ALPS Advisors's SLNO Position: Q4 2024 in Review

ALPS Advisors sold out of Soleno Therapeutics (SLNO) in Q4 2024, closing a stake of 29,168 shares — an estimated $1.47M sold.

ALPS Advisors first reported a position in SLNO in Q4 2023 and held it in 4 quarters. The position peaked at $1.47M in Q3 2024. 166 funds tracked by Wall St. Rank hold SLNO as of Q4 2024.

  • ALPS Advisors reported no remaining Soleno Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ALPS Advisors sold 29,168 Soleno Therapeutics shares in Q4 2024, an estimated $1.47M.
  • ALPS Advisors first reported a position in Soleno Therapeutics in Q4 2023 and held it in 4 quarters.
  • ALPS Advisors's Soleno Therapeutics position peaked at $1.47M in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.